North America Joint Pain Injection Market
The North America joint pain injection market is
In North America, especially the US witnessed an unprecedented rise in the number of COVID-19 cases, which led to the discontinuation of several business operations and manufacturing activities of various healthcare products, including joint pain injections, which negatively impacted the joint pain injection market. In order to manage the outbreak, government took preventive measures including total lockdowns and social distancing policies. In addition, medical device industry is also facing negative impact of this pandemic. As the COVID-19 pandemic continues to unfold, medical device companies are finding difficulties in managing their operations. Cancelling elective surgeries to reduce exposure to COVID-19 in the hospital and operating rooms into intensive care units is also negatively affecting the growth of the joint pain injection market. However, at end of second quarter, restrictions on orthopedic procedures were lifted by the US government and patients were also allowed to visit orthopedic offices. Such decisions helped market players to recover their losses during the pandemic.
Strategic insights for the North America Joint Pain Injection provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 2,785.42 Million |
| Market Size by 2028 | US$ 5,010.47 Million |
| Global CAGR (2021 - 2028) | 8.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Drugs
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The geographic scope of the North America Joint Pain Injection refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The joint pain injection market in North America is expected to grow from US$ 2,785.42 million in 2021 to US$ 5,010.47 million by 2028; it is estimated to grow at a CAGR of 8.7% from 2021 to 2028. Countries in North America are emerging as attractive outsourcing locations for pharmaceuticals and biopharmaceuticals industries. Flourishing domestic pharmaceutical market and increasing number of pipeline drugs are further opening new avenues for the contract manufacturers as well as generic drug manufacturing in the region. Additionally, to meet the growing demand, many contract-based organizations are expanding their manufacturing capabilities. Thus, the emerging markets hold high potential and huge revenue generation opportunities for the pharmaceutical manufacturing companies. According to a report published by the US Department of Health & Human Services in the year 2018 stated that near 700,000 knee replacement surgeries in US are being carried out every year. It is also expected that the number is likely to reach approximately 3.48 million surgeries per year till 2030. Other than the knee surgeries, the incidences of the hip replacement surgeries are also increasing in the ageing population. As per the Agency for Healthcare Research and Quality, over 450,000 total hip replacements are performed every year in the United States. Furthermore, as per the report published in The Journal of Rheumatology in the year 2018, stated that in US incidence of total hip replacement surgeries are expected to increase by 129% in 2030 which is around 850,000 replacements procedures and by 284% in 2040 that is about 1,429,000 replacements. The advancement is the technology has led into the reduction of the time for the surgeries.
Based on drugs, the corticosteroid segment accounted for the largest share of the North America joint pain injection market in 2020. Based on joint type, the knee segment accounted for the largest share of the North America joint pain injection market in 2020. Based on distribution channel, the hospitals pharmacies segment accounted for the largest share of the North America joint pain injection market in 2020.
A few major primary and secondary sources referred to for preparing this report on the North America joint pain injection market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report include Chugai Pharmaceutical Co., Ltd.; Bioventus Inc.; Fidia Pharma USA Inc.; Flexion Therapeutics, Inc.; Seikagaku Corporation; Ferring B.V.; Sanofi; Anika Therapeutics, Inc; OrthogenRx, Inc. and Teva Pharmaceutical Industries Ltd.
The North America Joint Pain Injection Market is valued at US$ 2,785.42 Million in 2021, it is projected to reach US$ 5,010.47 Million by 2028.
As per our report North America Joint Pain Injection Market, the market size is valued at US$ 2,785.42 Million in 2021, projecting it to reach US$ 5,010.47 Million by 2028. This translates to a CAGR of approximately 8.7% during the forecast period.
The North America Joint Pain Injection Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Joint Pain Injection Market report:
The North America Joint Pain Injection Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Joint Pain Injection Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Joint Pain Injection Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Joint Pain Injection Market
